Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children

PVX108 - Aravax

K. Perrett1; O. Michael2; P. Quinn3; L. Ford4; B. Vickery5; A. Voskamp6; P. Laidler6; A. Leahy6; J. Bingham6; S. Prickett7; P. Hickey6

Apr 22, 2024